Press Releases

Investors & Media

 
Press Releases
  Date Title and Summary View
Jun 30, 2014
CAMBRIDGE, Mass., June 30, 2014 /PRNewswire/ -- Minerva Neurosciences, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases, today announced the pricing of its initial public offering of 5,454,545 shares...
Jul 7, 2014
CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- Minerva Neurosciences (NASDAQ: NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Rogerio Vivaldi, MD, MBA, Minerva president and CEO, along with additional members of the senior leadership team, will ring the NASDAQ Stock Market C...
Jul 14, 2014
CAMBRIDGE, Mass., July 14, 2014 /PRNewswire/ -- Minerva Neurosciences (NASDAQ: NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Frederick W. Ahlholm has been appointed vice president of finance and chief accounting officer, effective June 2, 2014.  Mr. Ahlholm is a sen...
Jul 31, 2014
CAMBRIDGE, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that it will release second quarter financial results after market close on Thursday, August 7, 2014. Minerva management will host a webcast and...
Aug 7, 2014
- Advanced Lead Compound MIN-101 in Phase 2 Studies for Schizophrenia and Clinical Development of MIN-202 in Insomnia -- Management to host conference call today at 4:30 p.m. ET - CAMBRIDGE, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical stage biopharmaceutical company focused on the development an...
Aug 18, 2014
CAMBRIDGE, Mass., Aug. 18, 2014 /PRNewswire/ -- Minerva Neurosciences (NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Mark S. Levine has been appointed vice president and general counsel. In this position, Mr. Levine will be responsible for the company's legal affairs and w...
Aug 28, 2014
CAMBRIDGE, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Rogerio Vivaldi, president and chief executive officer of Minerva, will present at the Baird 2014 Health Care Conference on Thursday, Septe...
Sep 22, 2014
CAMBRIDGE, Mass., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that the U.S. Food and Drug Administration has completed its review of the Investigational New Drug Application for MIN-202, the Company's sele...
Oct 30, 2014
WALTHAM, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that it will release third quarter financial results after market close on Thursday, November 6, 2014. Minerva management will host a webcast and ...
Nov 6, 2014
- Advanced Lead Compound MIN-101 in Once-daily Formulation with Topline Results Expected in 4Q14; Phase 2b Study Expected to be Submitted in 4Q14 and Enrollment Expected to Begin in 1H15 -- Phase 1 Bioavailability Study for MIN-202 in Insomnia in U.S. Ongoing after FDA Acceptance of IND Application; Topline Results Expected in 4Q14 -- Management to...
Page:
1
... NextLast
= add release to Briefcase